Stocks · News reference
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — MapLight Therapeutics, Inc. (MPLT)
Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate
MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has